Kamrad Ilka, Henricsson Anders, Karlsson Magnus K, Magnusson Håkan, Nilsson Jan-Åke, Carlsson Åke, Rosengren Björn E
Departments of Orthopedics and Clinical Sciences , Lund University and Skåne University Hospital , Malmö ;
Acta Orthop. 2015;86(4):407-11. doi: 10.3109/17453674.2015.1018760. Epub 2015 Feb 12.
In failed total ankle replacements (TARs), fusion is often the procedure of preference; the outcome after exchanging prosthetic components is debated. We analyzed prosthetic survival, self-reported function, and patient satisfaction after component exchange. Patients and methods We identified patients in the Swedish Ankle Registry who underwent exchange of a tibial and/or talar component between January 1, 1993 and July 1, 2013 and estimated prosthetic survival by Kaplan-Meier analysis. We evaluated the patient-reported outcome measures (PROMs) SEFAS, EQ-5D, EQ-VAS, SF-36, and patient satisfaction by direct questions.
69 patients underwent revision TAR median 22 (0-110) months after the primary procedure. 24 of these failed again after median 26 (1-110) months. Survival analysis of revision TAR showed a 5-year survival rate of 76% and a 10-year survival of 55%. 29 patients with first revision TAR in situ answered the PROMs at mean 8 (1-17) years after revision and had the following mean scores: SEFAS 22, SF-36 physical 37 and mental 49, EQ-5D index 0.6, and EQ-VAS 64. 15 of the patients were satisfied, 5 were neither satisfied nor dissatisfied, and 9 were dissatisfied.
Revision TAR had a 10-year survival of 55%, which is lower than the 10-year survival of 74% for primary TAR reported from the same registry. Only half of the patients were satisfied. Future studies should show which, if any, patients benefit from revision TAR and which patients should rather be fused directly.
在全踝关节置换术(TAR)失败后,融合术通常是首选的治疗方法;更换假体组件后的疗效存在争议。我们分析了更换组件后的假体生存率、自我报告的功能以及患者满意度。患者与方法:我们在瑞典踝关节登记处识别出1993年1月1日至2013年7月1日期间接受胫骨和/或距骨组件更换的患者,并通过Kaplan-Meier分析估计假体生存率。我们通过直接询问评估患者报告的结局指标(PROMs),即瑞典踝关节功能评分(SEFAS)、欧洲五维度健康量表(EQ-5D)、EQ视觉模拟量表(EQ-VAS)、简短健康调查量表(SF-36)以及患者满意度。
69例患者在初次手术后中位时间22(0 - 110)个月接受了翻修TAR。其中24例在中位时间26(1 - 110)个月后再次失败。翻修TAR的生存分析显示,5年生存率为76%,10年生存率为55%。29例初次翻修TAR原位的患者在翻修后平均8(1 - 17)年回答了PROMs问题,其平均得分如下:SEFAS为22分,SF-36身体维度为37分,精神维度为49分,EQ-5D指数为0.6,EQ-VAS为64分。15例患者满意,5例患者既不满意也不不满意,9例患者不满意。
翻修TAR的10年生存率为55%,低于同一登记处报告的初次TAR的10年生存率74%。只有一半的患者满意。未来的研究应表明哪些患者(如果有的话)能从翻修TAR中获益,哪些患者更适合直接进行融合术。